What do systematic reviews say?

Intervention not reported

• Oral isotretinoin for acne 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 351 participants
  Low

Azoles vs terbinafine

Azole probably leads to lower clinical cure compared with terbinafine (moderate certainty).

• Oral antifungal medication for toenail onychomycosis 2017 · Cochrane Headline outcomes only
  RR 0.82 [0.72, 0.95]
  15 studies · 2168 participants
  Moderate

Complete cure and adverse events for terbinafine vs placebo

The review found no eligible studies for this question.

• Oral antifungal medication for toenail onychomycosis 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Azoles vs placebo

Azole leads to higher clinical cure compared with placebo (high certainty).

• Oral antifungal medication for toenail onychomycosis 2017 · Cochrane Headline outcomes only
  RR 22.18 [12.63, 38.95]
  9 studies · 3440 participants
  High

Azoles vs placebo

Azole leads to higher mycological cure compared with placebo (high certainty).

• Oral antifungal medication for toenail onychomycosis 2017 · Cochrane Headline outcomes only
  RR 5.86 [3.23, 10.62]
  9 studies · 3440 participants
  High

Azoles vs placebo

Azole showed no clear difference in adverse events compared with placebo (moderate certainty).

• Oral antifungal medication for toenail onychomycosis 2017 · Cochrane Headline outcomes only
  RR 1.04 [0.97, 1.12]
  9 studies · 3441 participants
  Moderate

Azoles vs placebo

Azole showed no clear difference in recurrence rate compared with placebo (low certainty).

• Oral antifungal medication for toenail onychomycosis 2017 · Cochrane Headline outcomes only
  RR 0.55 [0.29, 1.07]
  1 study · 26 participants
  Low

Azoles vs placebo

The review found no eligible studies for this question.

• Oral antifungal medication for toenail onychomycosis 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Griseofulvin vs azole

Griseofulvin showed no clear difference in clinical cure compared with azole (moderate certainty).

• Oral antifungal medication for toenail onychomycosis 2017 · Cochrane Headline outcomes only
  RR 0.94 [0.45, 1.96]
  5 studies · 222 participants
  Moderate

Griseofulvin vs azole

Griseofulvin showed no clear difference in mycological cure compared with azole (moderate certainty).

• Oral antifungal medication for toenail onychomycosis 2017 · Cochrane Headline outcomes only
  RR 0.87 [0.5, 1.51]
  5 studies · 222 participants
  Moderate

Griseofulvin vs azole

Griseofulvin probably leads to higher adverse events compared with azole (moderate certainty).

• Oral antifungal medication for toenail onychomycosis 2017 · Cochrane Headline outcomes only
  RR 2.41 [1.56, 3.73]
  2 studies · 143 participants
  Moderate

Griseofulvin vs azole

It is very uncertain whether griseofulvin changes recurrence rate compared with azole (very low certainty).

• Oral antifungal medication for toenail onychomycosis 2017 · Cochrane Headline outcomes only
  RR 4 [0.26, 61.76]
  1 study · 7 participants
  Very low

Azoles vs terbinafine

Azole probably leads to lower mycological cure compared with terbinafine (moderate certainty).

• Oral antifungal medication for toenail onychomycosis 2017 · Cochrane Headline outcomes only
  RR 0.77 [0.68, 0.88]
  17 studies · 2544 participants
  Moderate

Griseofulvin vs azole

The review found no eligible studies for this question.

• Oral antifungal medication for toenail onychomycosis 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Griseofulvin vs terbinafine

Griseofulvin may leads to lower clinical cure compared with terbinafine (low certainty).

• Oral antifungal medication for toenail onychomycosis 2017 · Cochrane Headline outcomes only
  RR 0.32 [0.14, 0.72]
  4 studies · 270 participants
  Low

Griseofulvin vs terbinafine

Griseofulvin may leads to lower mycological cure compared with terbinafine (low certainty).

• Oral antifungal medication for toenail onychomycosis 2017 · Cochrane Headline outcomes only
  RR 0.64 [0.46, 0.9]
  5 studies · 465 participants
  Low

Griseofulvin vs terbinafine

Griseofulvin may leads to higher adverse events compared with terbinafine (low certainty).

• Oral antifungal medication for toenail onychomycosis 2017 · Cochrane Headline outcomes only
  RR 2.09 [1.15, 3.82]
  2 studies · 100 participants
  Low

Griseofulvin vs terbinafine

The review found no eligible studies for this question.

• Oral antifungal medication for toenail onychomycosis 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Griseofulvin vs terbinafine

The review found no eligible studies for this question.

• Oral antifungal medication for toenail onychomycosis 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Combination terbinafine plus azole vs terbinafine

It is very uncertain whether combination terbinafine plus azole changes clinical cure compared with terbinafine monotherapy (very low certainty).

• Oral antifungal medication for toenail onychomycosis 2017 · Cochrane Headline outcomes only
  RR 1.41 [1.01, 1.97]
  1 study · 176 participants
  Very low